Mirvetuximab Soravtansine, a Folate Receptor Alpha (FRα)-targeting Antibody-drug Conjugate (ADC), in Combination with Bevacizumab in Patients (pts) with Platinum-resistant Ovarian Cancer: Final Analyses from the FORWARD II Study
ASCO 2019
IMMUNOGEN IS NOW PART OF ABBVIE
Together we will be working to make a remarkable impact for cancer patients and their communities of care, raising standards of care and advancing a dynamic oncology pipeline.